Metabolomic analysis reveals potential biomarkers and serum metabolomic profiling in spontaneous intracerebral hemorrhage patients using UPLC/quadrupole time‐of‐flight MS

Abstract

Spontaneous intracerebral hemorrhage (ICH) accounts for 10-20% of all strokes and contributes to higher mortalities and severe disabilities. The aims of this study were, therefore, to characterize novel biomarkers, metabolic disruptions, and mechanisms involving ICH. A total 30 ICH patients and 30 controls were enrolled in the study, and their clinical characteristics were analyzed. Nontargeted metabolomic analysis was conducted using ultra-performance liquid chromatography quadrupole time-of-flight tandem mass spectrometry (UPLC/Q-TOF). Multivariate statistical analysis and receiver operating characteristic curve analysis were used for screening and evaluating the predictive ability of biomarkers. ICH patients showed significantly higher systolic blood pressure, diastolic blood pressure, blood glucose levels, white blood cell counts, neutrophil count, percentage of neutrophils and globulin and a lower albumin/globin ratio when compared with controls. In sum, 11 important metabolites were identified, which were associated with disruption of fatty acid oxidation and sphingolipid and phospholipid metabolism, as well as increased inflammation, oxidative stress, and vascular pathologies. Further multiple logistic regression analyses of these metabolites showed that L-carnitine and phosphatidylcholine (20:3/22:6) have potential as biomarkers of ICH, and the area under the curve, sensitivity, specificity were 0.974, 90%, and 93%, respectively. These findings provide insights into the pathogenesis, early prevention, and diagnosis of ICH.

Metabolomic Analysis in Neurocritical Care Patients

“…Our search resulted in one study related to metabolome profiling in ICH patients. Sun et al, 2021 performed non-targeted metabolomic analysis on serum samples obtained from ICH patients [ 19 ]. The study identified 11 metabolites of significance that are associated with multiple pathophysiological pathways following ICH.…”

Metabolomics as a potential tool for monitoring patients with aneurysmal subarachnoid hemorrhage

“…Still, in the clinical setting, imaging modalities used for diagnosis may not reveal any changes early on and may be time-consuming, demonstrating the need for novel and sensitive biomarkers for early diagnosis. Thus far, studies were able to identify metabolomic biomarkers of transient ischemic attack (TIA) ( 35 ), ischemic ( 26 , 36 ) and hemorrhagic stroke ( 37 , 38 ), metabolites capable of distinguishing between the stroke types ( 39 – 41 ) and stages ( 42 ), but also to differentiate between stroke and stroke mimics ( 43 ). It is evident that there is strong diagnostic potential from discovering differential biomarkers.…”